Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07080619
PHASE2

SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers

Sponsor: Tianjin ConjuStar Biologics Co., Ltd.

View on ClinicalTrials.gov

Summary

This study is an open-label, multicenter Phase IIa trial to evaluate the efficacy and safety of SC-101 monotherapy in patients with locally advanced or metastatic malignant tumors who are positive for NECTIN4 gene amplification.

Official title: A Phase IIa Clinical Study to Assess the Efficacy and Safety of SC-101 in Patients With Advanced Malignant Tumors Positive for NECTIN4 Gene Amplification

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

120

Start Date

2025-09-20

Completion Date

2027-12-30

Last Updated

2025-09-11

Healthy Volunteers

No

Interventions

DRUG

SC-101

Receive 7.5 mg/m² of SC-101 intravenously once weekly (QW).